

Recovery of the gut microbiome following enteric infection and persistence of antimicrobial resistance genes in specific microbial hosts

Zoe A. Hansen,¹ Karla A. Vasco,¹ James T. Rudrik,⁴ Kim T. Scribner,²

Lixin Zhang,³ Shannon D. Manning^{1*}

Michigan State University, Departments of ¹Microbiology and Molecular Genetics, ²Fisheries and Wildlife, and ³Epidemiology and Biostatistics, E. Lansing, MI 48824; and ⁴the Michigan Department of Health and Human Services, Bureau of Laboratories, Lansing, MI 48906

E-mail addresses:

hansenzo@msu.edu; vascokar@msu.edu; RudrikJ@michigan.gov; scribne3@msu.edu;
lxzhang@msu.edu; mannin71@msu.edu

*Corresponding author: mannin71@msu.edu

1 Abstract

2 Enteric pathogens cause widespread foodborne illness and are increasingly found to harbor
3 antimicrobial resistance. The ecological impact of these pathogens on the human gut microbiome
4 and resistome, however, has yet to be fully elucidated. This study applied shotgun metagenome
5 sequencing to stools from 60 patients (cases) with enteric bacterial infections for comparison to
6 stools collected from the same patients' post-recovery (follow-ups). Overall, the case samples
7 harbored more antimicrobial resistance genes (ARGs) and had greater resistome diversity than
8 the follow-up samples ($p<0.001$), while follow-ups had much more diverse microbiomes
9 ($p<0.001$). Although cases were primarily defined by genera *Escherichia*, *Salmonella*, and
10 *Shigella* along with ARGs for multi-compound and multidrug resistance, follow-ups had a
11 greater abundance of Bacteroidetes and Firmicutes phyla and genes for tetracycline, macrolides,
12 lincosamides, and streptogramins (MLS), and aminoglycoside resistance. A host-tracking
13 analysis revealed that *Escherichia* was the primary carrier of ARGs in both cases and follow-ups,
14 with a greater abundance occurring during infection. Eleven distinct extended spectrum beta-
15 lactamases (ESBLs) were identified during infection, some of which appear to be lost or
16 transferred to different microbial hosts upon recovery. The increasing incidence of disease
17 caused by foodborne pathogens, coupled with their evolving role in harboring and transferring
18 antimicrobial resistance determinants within communities, justifies further examination of the
19 repercussions of enteric infection on human gut ecology.

20 **Introduction**

21 Foodborne illness caused by enteric pathogens impacts ~9.4 million people in the United
22 States each year, with over one-third being attributed to bacterial pathogens [1]. In 2019, the
23 Centers for Disease Control and Prevention (CDC) documented a marked increase in the
24 incidence of foodborne infection caused by *Campylobacter* and Shiga toxin-producing
25 *Escherichia coli* (STEC) [2]. *Salmonella* and *Shigella* also contribute to a high incidence of
26 infections, though case numbers remained unchanged relative to previous years. In addition to
27 their role in enteric disease, *Campylobacter*, non-Typhoidal *Salmonella*, *Shigella*, and members
28 of *Enterobacteriaceae* (e.g., *Escherichia*) have been classified by the CDC as serious threats for
29 harboring and transmitting antimicrobial resistance [2]. Indeed, each of these pathogens have
30 been shown to transfer ARGs horizontally within and between microbial species residing in a
31 niche [3]. Such resistance determinants can cross environmental boundaries, thereby increasing
32 frequencies within different hosts and environments and enhancing the likelihood of horizontal
33 gene transfer (HGT).

34 The consequences of enteric infection on the health of the human gut microbiome are not
35 fully understood. Prior studies conducted in our lab showed a marked decrease in gut microbiota
36 diversity attributed to enteric infection [4]. This lack of diversity was suggested to reduce
37 beneficial microbially-mediated metabolism and exacerbate gut inflammation [5]. Others have
38 also demonstrated an increase in the proportion of Proteobacteria upon infection with
39 *Salmonella*, *Campylobacter*, *Shigella*, and other pathogens in multiple host organisms [6-9].
40 More recently, we have documented shifts in the gut resistome, or compilation of antimicrobial
41 resistance genes (ARGs), among patients with *Campylobacter* infections when compared to their
42 healthy family members [10]. The potential ecological repercussions relevant to recovery from

43 enteric infection, however, have yet to be explored. If the microbiome demonstrates a certain
44 degree of resilience, then perturbations should not be felt with such amplitude and be resolved
45 over time [11]. In the context of pathogen invasion, various ecological interactions such as direct
46 antagonism from commensal microbes, resource competition and competitive exclusion, and
47 secondary metabolite production, must be considered [12, 13]. Each of these factors may
48 influence the success of an enteric pathogen in the gut environment and the ability of the human
49 host to recover from the acute infection.

50 Consideration must also be given to the invading pathogen, which can potentially
51 introduce virulence and antimicrobial resistance determinants into the gut community. Indeed,
52 pathogens harboring ARGs can transfer these to other gut microbes during infection or vice
53 versa, thereby transforming the gut into a resistance gene reservoir [14]. This reservoir is
54 particularly concerning given that pathobionts found in the community can acquire genetic
55 factors that encode for pathogenic properties as well as resistance to clinically important
56 antibiotics. Because infection with enteric pathogens was shown to alter the relative abundance
57 of certain microbial populations in the gut [4], it is probable that ARGs harbored by microbes
58 that “bloom” during infection will also increase in abundance. Although new sequence-based
59 approaches have been developed to identify the microbial hosts of specific ARGs in different
60 environments [15], these have not been applied to enteric infections.

61 Consequently, we used shotgun metagenome data to determine how infection by and
62 recovery from enteric pathogens influences the human gut resistome and microbiome. We also
63 sought to identify which microbial hosts harbor ARGs to advance understanding of how drug
64 resistance spreads and is maintained within the dysbiotic and healthy gut microbiome. Further
65 defining the impacts of these infections on the makeup and function of the gut microbiome is

66 necessary to counteract the dissemination of drug resistance and discover novel therapeutic
67 solutions.

68

69 **Methods**

70 **Sample collection and sequencing**

71 Sixty stools were obtained from patients with enteric infections (cases) caused by
72 *Campylobacter* (n=24), *Salmonella* (n=29) *Shigella* (n=4) and Shiga toxin-producing *E. coli*
73 (STEC) (n=3) from, 2011-2015. Stools were preserved in Cary-Blair transport media and
74 submitted to the Michigan Department of Health and Human Services (MDHHS) in
75 collaboration with four hospitals as described [4]. Patient demographics, exposures, and
76 symptoms were reported through the Michigan Disease Surveillance System (MDSS). Counties
77 were classified as ‘rural’ or ‘urban’ as was done in our prior analysis [10]. Each patient
78 submitted a follow-up sample 1 week to 29 weeks after their acute infection, yielding 120 paired
79 samples for analysis. Moreover, 91 household members (controls) linked to 38 of the 60 patients
80 submitted stools for comparison 5-29 weeks after the cases’ infection. Resistome data from
81 *Campylobacter* patients were examined previously [10], though no prior metagenome analyses
82 were performed on the post-recovery samples.

83 Metagenomic DNA was extracted, sheared, and normalized as described [4]. Libraries
84 were constructed using the TruSeq Nano library kit (Illumina, Inc., San Diego, CA, USA) and
85 shotgun sequencing was performed in four runs using an Illumina HiSeq 2500. Reads were
86 demultiplexed at the MSU Research Technology Support Facility and poor quality and
87 contaminated samples were removed after filtering.

88 **Reads-based identification of antimicrobial resistance genes (ARGs)**

89 The AmrPlusPlus v2.0 pipeline was used for quality control checking, aligning, and
90 annotating metagenomic fragments with the MEGAREs 2.0 database [16] and previously
91 described parameters [10]. Reads were mapped to human genome GRCh38
92 (GRCh38_latest_genomic.fna.gz, downloaded December 2020) in RefSeq using the Burrows-
93 Wheeler Aligner (BWA) [17] and removed using SAMTools [18] and BEDTools [19]. The non-
94 host FASTQ files were stored and aligned to MEGAREs 2.0 to identify ARGs using default
95 values for the BWA and SAMTools. Reads were deduplicated and annotated with
96 ResistomeAnalyzer (identity threshold of $\geq 80\%$) to quantify ARG abundance per sample, while
97 RarefactionAnalzyer estimated sequencing depth. Single nucleotide polymorphisms (SNPs)
98 requiring specific haplotypes to be classified as ARGs were also extracted for confirmation using
99 the Resistance Gene Identifier via the Comprehensive Antibiotic Resistance Database [20].
100 Following annotation and quantifying ARG abundances, MicrobeCensus [21] was used to
101 determine the average genome size and number of genome equivalents (GE) for normalizing
102 ARG and taxonomic abundances (**Additional file 1**). Lastly, metagenomic coverage was
103 estimated with Nonpareil [22] (**Additional file 2**).

104 **Assembly-based identification of ARGs**

105 The non-host FASTQ files were used for metagenome assembly after employing
106 BBTools for paired end read merging using the ‘bbmerge-auto.sh’ script. Reads that failed
107 merging were error-corrected using Tadpole [23] and reexamined. If merging continued to fail,
108 reads were extended 20 bp and merging was iterated up to five additional times or unmerged
109 reads were included. Assembly was performed with MEGAHIT [24] using the merged and

110 paired-end reads. The Quality Assessment Tool for Genome Assemblies [25] evaluated assembly
111 quality and coverage (**Additional file 3**).

112 A custom workflow was developed using anvi'o to analyze microbial genomes from
113 metagenomes as described [26]. Briefly, assembled contigs were reformatted using ‘anvi-script-
114 reformat-fasta’ to generate a contigs database per sample with ‘anvi-gen-contigs-database’. The
115 script ‘anvi-run-hmms’ was used to populate the contigs database with hits detected using
116 Hidden Markov Models, which improves assembly annotation. Prodigal [27] was used in the
117 script ‘anvi-get-sequences-for-gene-calls’ to obtain amino acid sequences of assembled genes for
118 use in the ARG-carrying contigs (ACC) analysis.

119 **Classifying microbial taxa**

120 Non-host paired-end reads were taxonomically annotated with Kaiju, a protein-based
121 classifier that translates reads to amino acid sequences while searching for maximum exact
122 matches (MEMs) among microbial reference genomes [28]. The National Center for
123 Biotechnology Information (NCBI) BLAST *nr* reference database was used with previously
124 published parameters [10]. Raw abundances of reads assigned to taxa were normalized by the
125 estimated number of GEs. Those sequencing reads without enough resolution were categorized
126 as “unassigned”, which comprised $\geq 50\%$ of annotated reads at the genus and species levels. The
127 composition analysis was restricted to assigned reads.

128 **Identifying bacterial hosts harboring ARGs**

129 Gene calls from anvi'o were used to identify ARG-carrying contigs (ACCs) by aligning
130 the amino acid sequences to the HMD-ARG database [29] using DIAMOND [30] using a
131 modified pipeline that was described previously [15, 31]. The SAM files were filtered to identify
132 contigs with gene hits, and Seqtk (<https://github.com/lh3/seqtk>) was used to extract the ACCs

133 from the genes as a FASTA file for alignment to the BLAST database v5.0 using blastp. An E-
134 value of 0.00001 cutoff was used with a maximum of 50 target sequences (i.e., 50 matches per
135 contig). One *Campylobacter* sample could not be annotated and was excluded along with the
136 paired follow-up sample leaving 59 pairs (118 samples) for analysis.

137 Alignment output was used to identify taxa associated with each ARG on a contig. Since
138 50 matches were allowed per contig, a custom Python script ‘ERIN_ACCpipeline_blastp_merge’
139 was used to quantify the average proportion of each genus per sample on the ACCs and the
140 average percentage of different ARGs per genus within all ACCs in a sample. Taxa with the
141 most hits per contig were considered the most likely to harbor a given ARG.

142 Abundance and diversity analyses

143 The identity and diversity of ARGs and taxa were determined among all samples. For the
144 resistome analyses, the gene, group, mechanism, class, and type levels were used [16]. Actual
145 estimated abundance of ARGs and taxa was determined by normalizing raw abundance counts to
146 the number of GE per sample. Relative abundance was calculated by dividing the number of GE-
147 normalized reads assigned to a specific feature by the total number of GE-normalized reads for
148 that sample. Alpha diversity metrics such as richness, Shannon diversity, and the Pielou’s
149 evenness score were estimated using the vegan package [32] in R (<https://www.R-project.org/>).
150 Nonparametric tests evaluated differences between groups and the Shapiro-Wilk test indicated
151 that both the resistome and microbiome data were not normally distributed (**Additional file 4**).

152 The Wilcoxon signed-rank test was used to detect significant differences between paired
153 samples, whereas the Wilcoxon rank-sum test was applied to unpaired samples. Beta diversity
154 metrics and ordination plots (e.g., Principal Coordinate Analysis (PCoA)) based on Bray-Curtis
155 dissimilarity at the gene and group (ARGs) or species and genus (taxa) levels were also

156 estimated with vegan [32]. The overall mean dissimilarity among cases and follow-ups was
157 compared to the mean dissimilarity between paired samples using a Welch's t-test (**Additional**
158 **file 5**). A Permutational Analysis of Variance (PERMANOVA) was calculated using the Bray-
159 Curtis dissimilarities in R to assess differences in centroids (mean) between cases and follow-ups
160 for both the resistome and microbiome composition; Permutational Analysis of Multivariate
161 Dispersion (PERMDISP) detected differences in dispersion (degree of spread) of these groups.

162 **Differential abundance of taxa and ARGs**

163 To assess representative features in cases and follow-ups, MMUPHin was used to
164 construct general linear models relating sample features to relative abundances [33]. Batch
165 adjustment of relative abundance data was performed by sequencing run, which significantly
166 influenced the distribution of points in the microbiome ordination (**Additional file 6**). To
167 identify differentially abundant ARGs and taxa, a linear model was constructed with follow-ups
168 serving as the reference for the fixed effect. Age in years, average genome size, number of GE,
169 year of collection, and use of antibiotics were included as covariates. Significance values were
170 adjusted using the Benjamini-Hochberg method of correction for multiple hypothesis testing (q-
171 value representing False Discovery Rate). The Analysis of Compositions of Microbiomes with
172 Bias Correction (ANCOM-BC) method [34], which considers absolute abundances from the GE-
173 normalized counts as input but cannot implement a mixed model with fixed and random effects,
174 was used for differential abundance testing. The data were concordant with MMUPHin data at
175 each comparison level (**Additional file 7**), though differences in rank of correlation was
176 observed for some features.

177 **Identification of continuous population structure**

178 MMUPHin [33] was also used to identify continuous population structure from the
179 microbiome and resistome abundance data to identify taxonomic or resistance gene tradeoffs that
180 impact data structure in ordination. The ‘continuous_discover()’ function was applied to the
181 abundance data, which performs unsupervised continuous structure discovery using Principal
182 Components Analysis (PCA). Continuous structure scores (called “loadings”) that comprise the
183 top principal components were compared across batches to identify “consensus” loadings
184 assigned to microbial features. The ‘var_perc_cutoff()’ parameter, which filters out the top
185 components accounting for a set proportion of the variability within the samples, was set to 0.75
186 for phylum and ARG class levels, 0.50 for genus and ARG groups, and 0.40 for species. Plots
187 were constructed to visualize the drivers of continuous data structure and to overlay data onto
188 ordination plots based on Bray-Curtis dissimilarity of microbiome or resistome relative
189 abundances.

190

191

192 **Results**


193 **Study population**

194 Among the 60 cases, 28 were male (46.7%) and 32 were female (53.3%) ranging between
195 1.5 and 90 years of age; most patients were between 19-64 years (n=26; 43.3%) or less than 9
196 (n=16; 26.7%). No difference in the proportion of stool submissions was observed by year,
197 though the fewest (n=13.3%) were recovered in 2011 and the most (36.7%) in 2013. Among the
198 59 patients reporting symptoms, 50 (84.8%) had abdominal pain, 57 (96.6%) reported diarrhea,
199 and 22 (37.3%) reported blood in the stool. Seventeen (28.3%) cases required hospitalization and

200 33 (55.0%) resided in a rural area. Most cases did not take antibiotics within two weeks of
201 sampling, though two (3.3%) reported amoxicillin use, while five (8.3%) reported use of
202 amoxicillin (n=2), azithromycin (n=1), ciprofloxacin (n=1), or an unknown antibiotic (n=1)
203 before submitting the follow-up sample. Most follow-up samples were collected 51-100 days
204 (n=20; 33.9%) or 101-150 days (n=28; 47.5%) post-infection, however, a small number was
205 submitted ≤ 50 (n=4; 6.78%) or > 150 (n=7; 11.9%) days after the initial sample was collected; the
206 date was missing for one patient. The range of follow-up submissions was 8 to 205 days post-
207 recovery with an average of 107.9 days.

208 **Changes in resistome composition and diversity post-recovery**

209 Among the 120 stool samples, 1,212 ARGs were identified encoding resistance to
210 biocides, antibiotic drugs, metals, and multi-compound substrates comprising 474 distinct gene
211 groups or operons. These genes represented 120 distinct mechanisms conferring resistance to 44
212 classes of compounds. In all, the case samples had significantly more diverse resistomes than
213 follow-up samples with a greater mean ARG richness ($S_{\text{cases}}=254$ vs. $S_{\text{follow-ups}}=103$; $p=4.5\text{e-}10$)
214 (**Figure 1**). The Shannon Diversity Index was also greater in cases than follow-ups ($H_{\text{cases}}=4.79$
215 vs. $H_{\text{follow-ups}}=3.36$; $p=2.1\text{e-}10$) as was the Pielou's evenness index ($J'_{\text{cases}}=0.87$ vs. $J'_{\text{follow-}}$
216 $_{\text{ups}}=0.80$; $p=8.1\text{e-}10$). Notably, the family member controls did not significantly differ from
217 follow-up samples, suggesting recovery to a “normal” state post-infection (**Additional file 8**).



218


219 **Figure 1. Resistome diversity is greater during infection than after recovery.** Three alpha
220 diversity measures (Richness, Shannon's Diversity Index, and Pielou's Evenness Index) are
221 presented. Case samples (Case) are indicated with green dots and follow-up samples (FollowUp)
222 are purple. Points are slightly offset from the vertical to allow interpretation of all samples. The
223 median of each measure is indicated by the thick bar within each box and the first and third
224 quartiles are indicated at the bottom and top of the box, respectively. Gray lines between points
225 connect both samples from the same individual. P-values were calculated using the Wilcoxon
226 signed-rank test for paired samples and are shown above the comparison bar within each plot.

227

228 The resistome composition also differed during and after infection as was demonstrated
229 in the PCoA based on the Bray-Curtis dissimilarity (PERMANOVA $p=0.000999$; $F=38.75$)
230 (**Figure 2**). No difference was observed in the level of dispersion between groups (PERMDISP

231 p=0.52; F=0.468). The samples from those reporting antibiotic use did not cluster separately
232 from those without antibiotics. Data for residence type, antibiotic use, gender, age, hospital,
233 county of origin, stool type, sequencing run, and number of days between samplings were fit to
234 the ordination. Age in years (p=0.013) and year of collection (p=0.043) independently influenced
235 the distribution of points, whereas residence location, hospital, and the number of days since
236 infection only trended toward significance. The pathogen responsible for the acute infections did
237 not have a significant effect on alpha or beta diversity trends (**Additional file 9**).


238



239 **Figure 2. Resistome composition differs significantly during and after infection.** A Principal
240 Coordinates Analysis (PCoA) plot of case (green circles) and follow-up (purple, squares)
241 resistomes based on Bray-Curtis dissimilarity calculated from gene-level abundances. The first
242 and second coordinates include the corresponding percentage of similarity explained. Patients
243 that used antibiotics two weeks prior to sample collection are indicated by triangular data points.

244 **Changes in microbiome composition and diversity post-recovery**

245 A total of 40,022 species, 4,851 genera, 1,157 families, 537 orders, 236 classes, and 224
246 phyla was found in all samples combined. Notably, the follow-up samples had more diverse gut
247 microbiomes than the cases (**Figure 3**) with significantly greater mean species richness
248 ($S_{\text{cases}}=3,426$, $S_{\text{follow-ups}}=5,789$; $p=2.5\text{e-}08$), mean evenness ($J'_{\text{case}}=0.150$, $J'_{\text{follow-up}}=0.190$; $p=9.8\text{e-}06$), and Shannon Diversity ($H_{\text{cases}}=1.21$, $H_{\text{follow-ups}}=1.65$; $p=1.3\text{e-}06$). When compared to control
249 samples, the follow-ups had similar Shannon Diversity and evenness, though the richness
250 differed ($S_{\text{follow-ups}}=5,789$, $S_{\text{controls}}=6,872$; $p=0.012$, Wilcoxon rank-sum test (two-sided,
251 unpaired); **Additional file 8**).




253

254 **Figure 3. Microbiome diversity is greater after recovery.** Box plots show the resistome alpha
255 diversity measures (Pielou's Evenness Index, Richness, Shannon Diversity Index). Separate
256 points represent case (Case, green) and follow-up (FollowUp, purple) samples and are offset

257 from the vertical for clarity. The median is indicated by the thick bar, while the first and third
258 quartiles are represented by lines at the bottom and top of the box, respectively. Gray lines
259 connect samples from one individual. P-values were calculated using the Wilcoxon signed-rank
260 test for paired samples and are shown above the comparison bars.

261

262 The microbiome composition was also significantly different in the case and follow-up
263 samples (PERMANOVA $p=0.000999$, $F=7.31$; **Figure 4**), though no difference in the dispersion
264 of points between groups was observed (PERMDISP $p=0.086$; $F=2.86$). The same extrinsic
265 covariates were fitted to the PCoA. Age ($p=0.008$), sequencing run ($p=0.001$), average genome
266 size ($p=0.001$), number of genome equivalents ($p=0.001$), year of sampling ($p=0.005$), days to
267 follow-up ($p=0.013$), hospital ($p=0.030$), and antibiotic use ($p=0.008$) significantly impacted the
268 point distribution. Similar to the resistome analysis, no differences were observed across
269 pathogens (**Additional file 10**).




270 **Figure 4. Microbiome compositional differences between cases and follow-ups are nuanced.**

271 A Principal Coordinates Analysis plot is shown for case (Case, green circles) and follow-up
272 (FollowUp, purple squares) microbiomes based on Bray-Curtis dissimilarity at the species level.
273 A biplot was overlaid to display variables that had a significant influence on the distribution of
274 points in the ordination. Age (Age.years), number of follow-up days (Followup.days), antibiotic
275 use (Yes and No) were influential vectors. The first and second coordinate are shown and include
276 the corresponding percentage of similarity explained. Patients that self-reported use of antibiotics
277 two weeks prior to sample collection are indicated by triangular data points.

278 **ARG composition and abundance varied during and after infection.**

279 The relative abundance of ARGs differed between groups (**Additional file 11**). The top-
280 three resistance classes in cases accounted for 39.8% of the total resistance genes relative to
281 71.0% for follow-ups, supporting the observation of greater resistome diversity during infection.
282 Classes for drugs and biocides (15.1%), MLS (13.3%), and multi-metals (11.3%) were most
283 abundant in cases compared to MLS (33.5%), tetracyclines (22.0%), and aminoglycosides
284 (15.5%) in the follow-ups (**Figure 5**). In the differential abundance analysis, classes for multi-
285 metal resistance (coef= -0.243; q-value=1.04e-04), drug and biocide resistance genes (coef= -
286 0.243; q-value= 1.46e-03), drug, metal, biocide resistance (coef=-0.212; q-value=7.86e-09), and
287 fluoroquinolone resistance genes (coef= -0.168; q-value= 8.19e-10) were more abundant in cases
288 (**Additional file 12**). Comparatively, tetracycline resistance genes (coef=0.352; q-value=2.26e-
289 05) were more abundant in the follow-up samples followed by MLS (coef=0.251; q-
290 value=1.49e-25) and aminoglycoside (coef=0.118; q-value= 7.86e-09) genes.

291



292 **Figure 5. Relative abundance of the top-10 resistance gene classes differs between case and**
293 **follow-up samples.** The top-10 most abundant compound classes is shown for cases (Case, top
294 panel) and follow-ups (FollowUp, bottom panel). Each column represents the resistome from one
295 individual and columns are ordered by the paired samples, meaning that the column position in
296 each side of the plot refers to the same individual during or after infection. Relative abundances
297 were determined using raw gene abundances normalized by the approximate number of genome
298 equivalents in the sample as determined using MicrobeCensus [21]. CAP = cationic
299 antimicrobial peptides; MLS = Macrolide, Lincosamide, Streptogramin; MDR = Multidrug
300 resistance; QACs = Quaternary Ammonium Compounds.

301 At the group level, specific ARGs were identified for the predominant classes. In the
302 cases, the most abundant groups were MLS23S (11.9%) conferring MLS resistance, *rpoB*
303 (2.8%), a rifampin resistance gene, and A16S (3.8%), which is important for aminoglycoside
304 resistance (**Additional file 13**). Similarly, the differential abundance analysis detected MDR
305 genes, *rpoB* (coef= -0.123; q-value=6.30e-05) and *mdtC* (coef= -0.103; q-value=4.97e-09), to be
306 the most differentiating ARG groups for cases (**Additional file 12**). Genes such as *parC* (coef= -
307 0.102; q-value= 3.90e-11) and *gyrA* (coef= -0.101; q-value=7.38e-08), that encode resistance to
308 fluoroquinolones, were also more abundant in cases.

309 In the follow-ups, the most abundant groups were for MLS, tetracycline, and
310 aminoglycoside resistance, with MLS23S (n=6.6; 24.3%), *tetQ* (n=4.0; 17.0%), A16S (n=2.4;
311 9.5%), and *cfx* (n=0.84; 3.8%) predominating, respectively (**Additional file 13**). *tetQ* had the
312 greatest differential abundance in favor of follow-ups (coef=0.30; q-value=6.56e-05)
313 (**Additional file 12**). Despite its noted prevalence among cases, MLS23S was also a defining
314 group for follow-ups since it comprised a greater proportion of ARGs (coef=0.172; q-
315 value=5.54e-06). The *cfx* (coef=0.124; q-value=0.0078) and other genes important for MLS
316 resistance such as *mefE* (coef=0.08; q-value=3.54e-07) and *ermF* (coef=0.07; q-value=3.68e-08),
317 were also more abundant in the follow-ups as were aminoglycoside resistance genes *ant(6)*
318 (coef= 0.103; q-value=5.23e-04) and A16S (coef= 0.092; q-value=5.14e-04).


319

320 **Taxa composition and abundance differ markedly during and after infection.**

321 Although both cases and follow-ups were dominated by Bacteria (relative abundance =
322 82.0% and 84.4%, respectively) with fewer Archaea or Eukarya, the members of this kingdom
323 comprising the respective microbiomes were distinct. During infection, cases had a high
324 proportion Proteobacteria (37.1%) with decreased abundance of Bacteroidetes (29.6%) and

325 Firmicutes (13.7%) (**Figure 6**). It is notable that a large proportion of reads could not be assigned
326 to the Phylum level for both the case (16.4%) and follow-up (13.5%) samples. In the differential
327 abundance analysis, Proteobacteria strongly represented cases as well (coef= -0.461; q-
328 value=9.35e-28).

329



330 **Figure 6. Relative abundance of microbial phyla differs between cases and follow-ups.** The
331 top-10 microbial phylum with the greatest average relative abundance among cases (Case, top
332 panel) or follow-ups (FollowUp, bottom panel) is shown; each column represents the
333 microbiome from one individual. Columns are ordered by their sample pairing (i.e., the column

334 position in each plot corresponds to the same individual. Relative abundances were determined
335 using raw gene abundances that had been normalized by the approximate number of genome
336 equivalents in the sample as determined using MicrobeCensus [21].

337
338 At the genus level, cases and follow-ups each had high proportions of reads that could not
339 be assigned to a specific genus (case=50.1%; follow-up=46.9%). Beyond this, *Bacteroides* was
340 the most prevalent in both the cases and follow-ups (14.5% and 18.7%, respectively). In cases,
341 this followed by two prominent members of the *Enterobacteriaceae* family within
342 Proteobacteria: *Salmonella* (7.1%) and *Escherichia* (5.0%) (**Additional file 14**). The next highest
343 relatively abundant genus in cases was *Pseudomonas* (2.8%), which is also a member of
344 Proteobacteria. In concordance with these findings, the differential abundance analysis identified
345 *Escherichia* (coef= -0.156; q-value=0.0021) as the predominant genus among the cases, which is
346 mainly represented by *Escherichia coli* (coef=-0.146; q-value=0.0082) (**Additional file 15**).
347 Moreover, *Shigella* (coef= -0.057; q-value=0.0059), which was represented by three species (*S.*
348 *sonnei*, *S. flexneri*, and *S. dysenteriae*), as well as *Enterobacter* (coef= -0.020; q-value= 1.10e-
349 08) and *Citrobacter* (coef= -0.017; q-value= 8.07e-06) were also more abundant in the cases.

350 In follow-ups, both the Bacteroidetes and Firmicutes populations appeared to rebound
351 during recovery and were notably more prevalent (49.3% and 26.9%, respectively). These phyla
352 also defined follow-ups in the differential abundance analysis (Bacteroidetes (coef=0.305; q-
353 value=1.87e-05); Firmicutes (coef=0.199; q-value= 4.61e-07)). Specifically, increases in
354 beneficial genera such as *Alistipes* (5.0%) and *Prevotella* (2.5%) from the Bacteroidetes phylum
355 were observed. The differential abundance analysis, however, detected Firmicutes genera
356 comprising *Roseburia* (coef=0.050; q-value=6.28e-05), *Dialister* (coef=0.038; q-value=0.0036),
357 and *Ruminococcus* (coef=0.037; q-value=2.83e-06) to predominate. *Phocaeicola* was the most


358 abundant genus of Bacteroidetes (coef=0.037; q-value=1.82e-08), which was represented by
359 *Phocaeicola vulgatus* and *Phocaeicola dorei*. One consistent finding among both methods is the
360 heightened abundance of *Akkermansia* (2.8%) from phylum Verrucomicrobia, a defining genus
361 of follow-ups (coef=0.033; q-value= 0.0069).

362 **The continuous structure of resistome and microbiome compositions**

363 For each level examined (e.g., phylum, genus, ARG class, ARG group), the top
364 contributing features were determined and relevant continuous structure scores were overlaid
365 onto ordination plots using MMUPHin [33]. When considering taxonomy, a tradeoff was
366 observed between the case dominant Proteobacteria phyla and Bacteroides and Firmicutes, which
367 were most abundant in follow-ups and only a subset of cases. At the genus level, an evident
368 gradient was observed between samples containing *Escherichia*, *Salmonella*, *Klebsiella*,
369 *Shigella*, and *Pseudomonas* versus those dominated by *Bacteroides* and *Alistipes* (**Figure 7A**).
370 These differences are visible when overlaid onto ordination as a gradient relevant to loading
371 score (**Figure 7B**). At the species level, which reveals gradients at the greatest resolution, we
372 observed a tradeoff between harboring *Escherichia coli*, *Klebsiella pneumoniae*, and *Shigella*
373 *sonnei* versus many *Bacteroides* species including *B. fragilis*, *B. stercoris*, *B. uniformis*, etc., and
374 *Phocaeicola* species such as *P. vulgatus* and *P. plebeius* (**Additional file 16**).

375 Tradeoffs were also observed for different resistance genes. At the class level, there was a
376 continuous gradient relative to tetracycline, MLS, and aminoglycoside dominant resistomes
377 versus ARGs for multi-metal resistance, drug and biocide resistance, and drug, metal, and
378 biocide resistance classes (data not shown). At the ARG group level, *tetQ* was identified as a
379 dominant driver of continuous structure scoring for follow-ups (**Figure 7C**), whereas resistance
380 genes such as *rpoB*, *acrA*, *acrB*, *mdtC*, and *mdtB* were defining for the opposite side of the PCoA

381 axis. Overlaying these loading scores onto ordination further revealed the taxonomic gradients
 382 among case and follow-up samples (**Figure 7D**).




383 **Figure 7. Continuous structure analysis reveals gradients driving the distribution of**
 384 **samples across the population.** The top consensus loadings of the PCA for **A)** genus and **C)**
 385 antibiotic resistance gene (ARG) groups are shown stratified by sample for cases (Case=red) and
 386 follow-ups (FollowUp=blue) drawn from the differential abundance analyses. The composition
 387 gradients at the **B)** genus and **D)** ARG group levels overlaid onto ordination plots based on Bray-
 388 Curtis dissimilarity. Cases (circles), follow-ups (squares), and individuals who received

389 antibiotics (triangles) are shown. The color gradient (“Score”) refers to the continuous structure
390 score affiliated with Loading 1 for phyla and genera, respectively. Juxtaposition of (A-C) and (B-
391 D) allow interpretation of tradeoffs within the samples.

392 **Different ARG-harboring microbial hosts are present in cases and follow-ups**


393 In cases, ACCs, on average, were primarily attributed to *Escherichia* (38.05%) followed
394 by *Salmonella* (18.31%) and *Klebsiella* (9.92%) (Figure 8). Of the *Escherichia*-associated
395 ARGs, 27.4% were assigned to MDR on average, though ARGs relevant to drug and biocide
396 resistance (8.12%), fluoroquinolone resistance (7.06%), and aminoglycoside resistance (6.21%)
397 were also identified. Comparatively, the *Salmonella*-associated ACCs mostly contained genes for
398 MDR and drug and biocide resistance (16.5% and 11.7%, respectively), while the *Klebsiella*
399 ACCs harbored an array of fosfomycin resistance genes (13.3%) followed by transposase genes
400 in the IS5 family (12.6%). *Klebsiella* ACCs also contained ARGs for elfamycin resistance
401 (10.4%) and MDR (9.08%).



402 **Figure 8. The top-10 genera assigned to antibiotic resistance gene (ARG)-carrying contigs**

403 **(ACCs) in case samples.** The percentages associated with each genus indicate the percent of
404 ACCs assigned to that genus. Each bar chart associated with a genus displays the top-5 or top-3
405 ARG classes affiliated with that particular genus on the ACCs.
406

407 Although the most prominent genus in follow-up ACCs was also *Escherichia* (19.81%),
408 the next most prevalent genera were classified as *Bacteroides* (15.12%) and *Faecalibacterium*
409 (5.99%) (Figure 9). Notably, the array of ARGs harbored in the *Escherichia*-associated ACCs
410 was nearly identical to cases with MDR genes predominating (25.1%), followed by resistance to
411 drugs and biocides (4.71%), fluoroquinolones (4.70%), and aminoglycosides (3.84%). Of the
412 *Bacteroidetes*-associated ACCs, genes for MLS, beta-lactam, and tetracycline resistance were
413 the most common. The 5.21% of the ACCs that could not be classified and represented an
414 “Uncultured” taxon harbored ARGs for tetracyclines, beta-lactams and phenicols.



415 **Figure 9. The top-10 genera assigned to antibiotic resistance gene (ARG)-carrying contigs**
416 **(ACCs) in follow-up samples.** The percentages associated with each genus indicate the percent

417 of ACCs assigned to that genus. Each bar chart associated with a genus displays the top-5 or top-
418 3 ARG classes affiliated with that particular genus on the ACCs.

419

420 **Microbes linked to case infections harbor ARGs during and after recovery**

421 Differences in ACCs were also identified after stratifying by the bacterium linked to each
422 infection. Among the 23 cases with *Campylobacter* (n=23) infections, for instance, the genera
423 comprising the greatest proportion of ACCs were *Escherichia* (42.84%), *Klebsiella* (10.01%),
424 and *Salmonella* (7.09%). Upon recovery, however, *Campylobacter* cases most often had ACCs
425 representing *Bacteroides* (18.34%), followed by *Escherichia* (17.31%) and *Faecalibacterium*
426 (6.76%). It is also notable that *Campylobacter* was in the top-20 genera represented on ACCs,
427 with proportions of 1.96% and 3.81% in cases and follow-ups, respectively. ARGs harbored by
428 *Campylobacter* in case samples conferred resistance to tetracyclines (27.6%), aminoglycosides
429 (9.92%), and rifampin (8.31%). Among the *Campylobacter* ACCs in follow-up samples,
430 tetracycline (29.0%) and aminoglycoside (27.0%) resistance genes were commonly detected as
431 were genes for MLS resistance (10.3%). Importantly, genes encoding resistance to
432 aminoglycosides were 2.7 times more prevalent among *Campylobacter* ACCs in the follow-up
433 samples relative to the case samples.

434 In the 29 cases with *Salmonella* infections, most ACCs were classified as *Escherichia*
435 (32.39%), *Salmonella* (30.96%), and *Klebsiella* (7.89%) compared to *Escherichia* (20.66%),
436 *Bacteroides* (14.16%), and *Faecalibacterium* (6.29%) for the follow-up samples. The most
437 common genes detected in *Salmonella* ACCs were important for multi-compound resistance
438 including drug and biocide resistance (14.1%) and MFS transporters (13.1%), which can have
439 MDR effects or high specificity to certain classes. ARGs for drug, biocide, and metal resistance
440 (7.61%) were also identified. Among the follow-up samples, the most prevalent class within

441 *Salmonella*-associated ACCs was RND efflux transporters (9.29%), followed by MFS
442 transporters (6.84%) and fluoroquinolone resistance genes (6.31%).

443 **Multiple clinically relevant ESBLs can be found after recovery from enteric infections**

444 In all, 49 distinct genes encoding beta-lactam resistance were identified representing class
445 A, C, and D beta-lactamases (**Additional file 17**); 11 (22.4%) were classified as distinct genes
446 encoding ESBL production that confer resistance to multiple beta-lactam antibiotics. Among the
447 ESBL genes detected, those belonging to the CepA family of class A beta-lactamases were most
448 prevalent occurring in 19 case and 13 follow-up samples; each gene was taxonomically assigned
449 to *Bacteroides*. Of these 19 cases, the gene was absent or “lost” in nine patients at follow-up
450 despite being detected in the case sample (**Additional file 18**). For the remaining 10 cases, the
451 same gene was detected in both the case and follow-up samples, indicating persistence with the
452 *Bacteroides* population. Additionally, three patients acquired a gene during the recovery period
453 as it was present in follow-up sample but not the initial sample collected during infection.

454 ESBL genes of the OXA family, which included OXA-1, OXA-50, OXA-51, and OXA-
455 61, were also detected; however, each gene was attributed to a different microbial host in the
456 ACC analysis and was only found in 2-3 individuals. Although the OXA-61 family of class D
457 beta-lactamases was harbored by *Campylobacter*, it was only found in two of the 23 cases with
458 *Campylobacter* infections. Similarly, *Klebsiella* was found to harbor OXY genes in four case
459 samples, though these were absent in the follow-up samples. *Klebsiella* also possessed genes
460 representing the SHV family of class A beta-lactamases, which were detected in eight cases.
461 Because SHV genes were also detected in two unpaired follow-ups, it is likely that all eight cases
462 lost the genes and two patients acquired it during recovery.

463 Genes representing the ADC family of class C ESBLs harbored by *Acinetobacter* were
464 also detected, though there was not enough evidence to infer transfer of these genes between
465 taxa. Since many of the ESBLs were present in cases but not follow-ups, we could not assess
466 whether they were transferred horizontally among bacteria during recovery. Other relevant beta-
467 lactamases were also identified including the BlaEC family of class C beta-lactamases, which
468 were primarily attributed to genus *Escherichia* and were found in 49 cases and 19 follow-ups.
469 Intriguingly, the ARG was lost in 35 cases, maintained in 14, and acquired in 5 follow-ups.

470 Genes encoding the CfxA family of class A broad-spectrum beta-lactamases were also
471 detected and were primarily harbored by *Bacteroides*, but also appeared within *Prevotella*.
472 Among these *Bacteroides*-associated ARGs, 46 were found in cases and 48 in follow-ups.
473 Although only 7 of these genes were lost by cases, 39 were maintained and 9 were acquired
474 during recovery. A similar trend was observed for *cfxA* within *Prevotella* as three of the five
475 cases lost the genes, two maintained them, and seven acquired them during recovery.
476 Interestingly, there is evidence of horizontal transfer of these CfxA genes between *Bacteroides*
477 and *Prevotella*. For example, six separate case-follow-up pairs show *cfxA* as being “acquired” by
478 *Prevotella* in follow-ups but also maintained by *Bacteroides*, suggesting potential *Bacteroides*-
479 to-*Prevotella* transfer. Two other case-follow-up pairs had *cfxA* maintained in both *Bacteroides*
480 and *Prevotella* during recovery, while there were three instances in which the *Prevotella*-
481 harbored ARG was “lost” and the *Bacteroides*-harbored *cfxA* was maintained, suggesting the
482 possibility of *Prevotella*-to-*Bacteroides* transfer.

483 Genes encoding the broad CMY-family of class C beta-lactamases were also identified
484 and assigned to *Salmonella* in 3 cases (all lost) and 2 follow-ups (both acquired). Relatedly, the
485 CMY-2 family of class C beta-lactamases was identified within *Citrobacter* and *Salmonella*.
486 Among these ARGs harbored by *Citrobacter*, 8 were found in case samples and 3 in follow-ups;

487 6 cases lost the gene, 2 maintained it, and one follow-up acquired it. Of the CMY-2 ARGs
488 harbored by *Salmonella*, two were found in cases (each of which were lost) and one was
489 acquired in a follow-up sample. Although the CMY family is a broader category than the CMY-2
490 family of beta-lactamases, it is possible that the CMY family defined in our study contains
491 CMY-2 genes relevant to this analysis. For example, there is one case-follow-up pair in which
492 the CMY-2 family was maintained in *Citrobacter* and the CMY family was acquired in
493 *Salmonella*; yet another case-follow-up pair indicated loss of the CMY family of beta-lactamases
494 in *Salmonella* but maintenance and noted increase of the CMY-2 family in *Citrobacter*.
495 Although loosely inferred, these data indicate the potential for the horizontal transfer of CMY-
496 family genes across genera.

497 Finally, genes for the general subclass A2 of class A beta-lactamases were found in
498 *Bacteroides* among both the cases (n=45) and follow-ups (n=47); 7 cases lost the gene during
499 recovery, while 38 maintained it and 9 follow-ups acquired it. The more general “class A beta-
500 lactamase” gene was also found in nine other genera including *Atlantibacter*, *Bacillus*,
501 *Burkholderia*, *Clostridium*, *Proteus*, *Salmonella*, *Yersinia*, *Escherichia*, and *Klebsiella*. Although
502 there is a slight difference in resolution of these identified features, it is helpful to consider the
503 potential for transference across genera.

504

505 **DISCUSSION**

506 The human gut microbiome, when disrupted by an infectious pathogen, can drastically
507 change in composition taxonomically, genetically, and functionally [35]. In most instances,
508 pathogen invasion leads to a state of dysbiosis linked to a decrease in gut microbiota diversity [4,
509 36]. Our study supports these findings, as markedly lower microbiome diversity was observed

510 among cases during infection than after recovery regardless of the bacterial pathogen causing
511 infection. The observed shifts in microbiome composition post-recovery are indicative of gut
512 health, as healthy family members (controls) and follow-ups had more similar microbiome
513 profiles than the cases. In addition to the increased microbiota diversity post-recovery, specific
514 taxonomic signatures such as enhanced abundance of Bacteroidetes and Firmicutes, were
515 observed. For instance, members of *Bacteroides*, *Prevotella*, and *Phocaeicola* as well as
516 *Faecalibacterium*, *Roseburia*, and *Ruminococcus* were found, which have been shown to play
517 influential roles in maintaining gut homeostasis and metabolic health [37-39]. By contrast, the
518 cases were defined primarily by members of Proteobacteria such as *Escherichia*, *Salmonella*,
519 *Shigella*, and *Klebsiella*, which have been linked to acute enteric disturbances as well as
520 prolonged dysbiosis and long-term disease outcomes [40].

521 The opposite was true for the collection of ARGs, as cases had greater resistome diversity
522 during infection than after recovery. Because shifts in microbial composition inherently
523 influence the presence and abundance of ARGs harbored by microbes within a community, this
524 finding is not surprising. Among the key differences observed, cases had more multi-compound
525 and multi-drug resistance genes during infection than post-recovery, whereas tetracycline, MLS,
526 and aminoglycoside resistance genes were more abundant in the recovered (follow-up) sample.
527 Diverse sets of ARGs have previously been found in otherwise healthy individuals as well [10,
528 41, 42], providing additional support for the human gut as an important reservoir of antibiotic
529 resistance determinants [14].

530 Intriguingly, a subset of five follow-up samples were more closely related to the case
531 microbiome and resistome samples in the PCoA. Because these patients had an average number
532 of 110 days since infection, which did not differ from the overall mean (n=108 days), other
533 factors likely contributed to the case-like microbiome profiles observed. Indeed, four patients

534 were either <10 or >50 years of age and two of these individuals were hospitalized. Since
535 children and older individuals typically have an enhanced risk of developing more severe disease
536 [43, 44], these patients could have experienced lengthier infections than other members of the
537 sample cohort. The same is true for those who were hospitalized and hence, the microbiome may
538 have not fully recovered at the time of follow-up sampling. The complete level of microbiome
539 recovery, however, could not be deduced for any of the patients since we did not evaluate the gut
540 microbiome in the same patients prior to infection. It is likely that the state of the microbiome
541 prior to infection as well as its resilience to disturbances will vary across individuals and greatly
542 impact the trajectory of disease and recovery. Implementation of a more rigorous longitudinal
543 study is therefore needed in the future.

544 In the host-tracking analysis, we demonstrated that specific microbial taxa were more
545 likely to harbor ARGs during infection. *Escherichia*, for instance, was a prominent host in the
546 cases regardless of the pathogen linked to the infection. Specifically, *Escherichia* comprised an
547 average of 38% of all ACCs, with most genes being important for MDR or multi-compound
548 resistance. This result is not surprising given the increased abundance of *Escherichia* observed
549 during infection. Expansion of *Escherichia* and Enterobacteriaceae in general, was previously
550 suggested to be linked to inflammation in the gut [45], which was also shown to augment HGT
551 rates between commensal and pathogenic members of this family [46]. Moreover, as the level of
552 MDR increases within a population, so too does the number of integrons, which were also shown
553 to persist among commensal *E. coli* [47]. This enhanced mobility and maintenance of resistance
554 determinants are key contributors to the emergence of resistant pathobionts [3, 48].

555 Evidence of ARGs harbored by genera linked to the acute infections was also observed,
556 indicating that some pathogens bring resistance genes into the gut during infection. In patients
557 with *Salmonella* infections, for instance, *Salmonella* accounted for ~31% of all ACCs compared

558 to the overall case average of 18%, with most genes encoding MDR or drug and biocide
559 resistance. Co-selection for resistance to antibiotics, metals, and biocides has been previously
560 documented in *Salmonella* and other foodborne pathogens [49]. This evidence is supported by
561 data generated in a co-occurrence network analysis despite being a less robust approach [50].
562 Notably, a *Salmonella*-specific subnetwork comprised of multiple metal, biocide, and MDR
563 genes was identified among *Salmonella* cases (**Additional file 20**). This subnetwork was not
564 detected in the co-occurrence network generated using data from the *Campylobacter* cases alone
565 (**Additional file 21**). Hence, these findings indicate that the different *Salmonella* pathogens
566 brought similar ARGs into the microbial communities at the time of infection. Future whole-
567 genome sequencing studies, however, should be conducted to characterize each pathogen and
568 determine the diversity and frequency of those ARGs that were introduced into each gut
569 community.

570 In the follow-up samples, *Escherichia* still accounted for the greatest proportion (~20%)
571 of all ARG-carrying contigs, which mostly contained MDR genes; however, the proportion was
572 1.9 times less than that observed during infection. Unlike the cases, *Bacteroides* was the second
573 most important genus accounting for ~15% of the ARG-carrying contigs at recovery with MLS,
574 beta-lactam, and tetracycline resistance genes predominating. Members of Bacteroidetes and
575 Firmicutes have previously been linked to high levels of tetracycline and erythromycin resistance
576 carrying genes such as *tetQ* as well as *ermF* and *ermG*, respectively [51]. These genes were
577 previously suggested to be maintained in microbial host populations even in the absence of
578 antibiotic selection, thereby enhancing the likelihood of HGT [51]. Although resistance to beta-
579 lactam antibiotics has been documented, variation in resistance rates has been observed across
580 species and geographic locations, particularly for the beta-lactamase producers [52, 53].

581 Indeed, the transfer and acquisition of genes encoding beta-lactamase production is of
582 great concern. During enteric infection, we detected 11 distinct ESBLs that varied in frequency
583 among the cases, although this number may underestimate the actual diversity as not all
584 sequences could be assigned a class designation. Except for the CepA family of genes, most
585 genes were “lost” or undetectable during recovery. This result is consistent with a prior study
586 showing that some ESBLs including CTX and SHV, were more readily lost, though this was
587 dependent on the bacterial host [54]. The noted roles of *Klebsiella* and *Escherichia* in harboring
588 ESBLs in both the case and follow-up samples calls attention to the documented capacity of
589 these genera to transfer genes across species or clonal lineages [55]. *Klebsiella*, for instance, was
590 a prominent ARG carrier in 9.2% and 4.6% of ACCs in the cases and follow-ups, respectively,
591 and was associated with a high occurrence of the IS5 family of transposases. The identification
592 of a genomic element with the potential to transfer ARGs within the gut microbiome is notable,
593 particularly to other members of *Enterobacteriaceae*, which have contributed to the widespread
594 distribution and spread of ESBL genes [2]. Several beta-lactamase genes were also detected that
595 were not classified as extended spectrum. The CfxA gene family, for example, was harbored by
596 both *Bacteroides* and *Prevotella*. In several paired case/follow-up samples, there is evidence for
597 the transfer of *cfxA* between genera, which has been documented previously [56]. Because this
598 evidence is solely based on the detection of the gene in both genera at two different time points,
599 more rigorous methods, such as characterizing the sequence-level similarity, are required for
600 confirmation.

601 There are other limitations related to the ACC analysis as well. One example is the
602 potential for misclassifying ARGs found on plasmids even though they were previously shown
603 to contain taxonomic information regarding the host microbe [57]. Because assembly of short-
604 read sequences can inaccurately characterize plasmids and other MGEs [58], deeper sequencing

605 is needed to generate more complete assemblies and avoid misclassifying the microbial hosts. In
606 addition, multiple ARGs were attributed to “uncultured” microbes, highlighting the need for
607 more comprehensive databases that can accurately predict host taxonomies. Finally, the ACC
608 analysis relies on classifying microbial hosts based on the co-occurrence of an ARG and its taxa
609 on the same contig. Alternative methods such as Single-molecule Real-time sequencing, are
610 therefore required in future studies. Despite these limitations, this study provides important data
611 about the most common alterations in the gut microbiome and resistome among patients with
612 enteric infections. It also illustrates how infected microbial communities recover, which is
613 needed to guide the development of more targeted intervention strategies or therapeutic options
614 aimed at restoring the dysbiotic gut. Future work should focus on understanding the trajectory of
615 recovery as it pertains to the presence and dissemination of drug resistance and characterizing the
616 interactions between microbial hosts, ARGs, and MGEs during recovery.

617 **Declarations**

618 **Ethics approval and consent to participate**

619 Study protocols and consent procedures were approved by the Institutional Review Boards at
620 Michigan State University (MSU; IRB #10-736SM) and the MDHHS (842-PHALAB) as well as
621 the four participating hospital laboratories.

622

623 **Availability of data and materials.**

624 Sequencing reads were deposited in the National Center for Biotechnology Information (NCBI)
625 sequence read archive (SRA) database under BioProjects PRJNA862908 and PRJNA660443
626 (BioSamples SAMN29999523 to SAMN29999673 and SAMN15958881 to SAMN15958950,
627 respectively). Bioinformatic scripts are at: github.com/ZoeHansen/PAPER_Hansen_Microbiome_2022.

628

629 **Competing interests.** The authors declare that they have no competing interests.

630

631 **Funding:** This work was supported by the National Institutes of Health [grant number
632 U19AI090872 to S.D.M. and J.T.R.]. Salary support was provided by the U.S. Department of
633 Agriculture [grant numbers 2019-67017-29112 to S.D.M.], the MSU Foundation (to S.D.M.),
634 and the Michigan Sequencing Academic Partnership for Public Health Innovation and Response
635 via the MDHHS and CDC (to S.D.M.). Student support for Z.A.H. was provided by the College
636 of Natural Science, the MSU Graduate School, and via the Ronald and Sharon Rogowski and
637 Thomas S. Whittam Graduate Awards from the MSU Department of Microbiology and
638 Molecular Genetics.

639

640 **Authors' contributions:** SDM and JTR conceptualized the study, obtained funds for the project,
641 and organized sample collection and processing. SDM supervised the study, and ZAH completed
642 the data analyses, figure generation, and developed the first manuscript draft. ZAH, SDM, KV,
643 KTS, and LZ assisted with additional analyses and manuscript revisions. All authors read and
644 approved the final manuscript.

645

646 **Acknowledgements**

647 We thank Ben Hutton and Jason Wholehan at the MDHHS for help with specimen processing
648 and culture as well as Rebekah E. Sloup, Katherine Jernigan, and Samantha Carbonell, for help
649 with community DNA isolation and sequencing. We also thank Dr. James M. Tiedje for his
650 ongoing and helpful discussions about these data.

651

652

653 **REFERENCES**

- 654 1. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson M-A, Roy SL, et al.
655 Foodborne illness acquired in the United States -- Major pathogens. *Emerg Infect Dis.*
656 2011;17(1):7-15.
- 657 2. Centers for Disease Control and Prevention (CDC): Antibiotic Resistance Threats in the
658 United States, 2019. Atlanta, GA; 2019. Available at:
659 <https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf>
- 660 3. Wallace MJ, Fishbein SRS, Dantas G. Antimicrobial resistance in enteric bacteria:
661 current state and next-generation solutions. *Gut Microbes.* 2020;12(1):e1799654; doi:
662 10.1080/19490976.2020.1799654.
- 663 4. Singh P, Teal TK, Marsh TL, Tiedje JM, Mosci R, Jernigan K, et al. Intestinal microbial
664 communities associated with acute enteric infections and disease recovery. *Microbiome.*
665 2015;3:45.
- 666 5. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of
667 human gut microbiome correlates with metabolic markers. *Nature.* 2013;500:541-6.
- 668 6. Huang AD, Luo C, Pena-Gonzalez A, Weigand MR, Tarr CL, Konstantinidis KT.
669 Metagenomics of two severe foodborne outbreaks provides diagnostic signatures and
670 signs of coinfection not attainable by traditional methods. *Appl Environ Microbiol.*
671 2017;83:e02577-16.
- 672 7. Argüello H, Estellé J, Zaldívar-López S, Jiménez-Marín Á, Carvajal A, López-Bascón
673 MA, et al. Early *Salmonella* Typhimurium infection in pigs disrupts microbiome
674 composition and functionality principally at the ileum mucosa. *Sci Rep.* 2018;8.
- 675 8. Haag L-M, Fischer A, Otto B, Plickert R, Kühl AA, Göbel UB, et al. Intestinal
676 microbiota shifts towards elevated commensal *Escherichia coli* loads abrogate
677 colonization resistance against *Campylobacter jejuni* in mice. *PLoS One.* 2012;7:e35988.
- 678 9. Yang J, Chen W, Xia P, Zhang W. Dynamic comparison of gut microbiota of mice
679 infected with *Shigella flexneri* via two different infective routes. *Exp Ther Med.* 2020;
680 19: 2273–2281.
- 681 10. Hansen ZA, Cha W, Nohomovich B, Newton DW, Lephart P, Salimnia H, et al.
682 Comparing gut resistome composition among patients with acute *Campylobacter*
683 infections and healthy family members. *Sci Rep.* 2021;11: 22368.
- 684 11. Lozupone C. Diversity, stability and resilience of the human gut microbiota. *Nature.*
685 2012;489:220-30.
- 686 12. Reid G, Howard J, Siang Gan B. Can bacterial interference prevent infection? *Trends*
687 *Microbiol.* 2001;9:424-8.
- 688 13. Sassone-Corsi M, Raffatellu M. No Vacancy: How beneficial microbes cooperate with
689 immunity to provide colonization resistance to pathogens. *J Immunol.* 2015;194:4081-7.
- 690 14. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic
691 resistance genes. *Trends Microbiol.* 2004;12:412-6.

692 15. Ma L, Li B, Jiang X-T, Wang Y-L, Xia Y, Li A-D, et al. Catalogue of antibiotic
693 resistome and host-tracking in drinking water deciphered by a large scale survey.
694 *Microbiome*. 2017;5:154.

695 16. Doster E, Lakin SM, Dean CJ, Wolfe C, Young JG, Boucher C, et al. MEGARes 2.0: A
696 database for classification of antimicrobial drug, biocide and metal resistance
697 determinants in metagenomic sequence data. *Nucleic Acids Res*. 2020;48(D1):D561-D9.

698 17. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform.
699 *Bioinformatics*. 2009;25:1754-60.

700 18. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence
701 alignment/map format and SAMtools. *Bioinformatics*. 2009;25:2078-9.

702 19. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic
703 features. *Bioinform App Note*. 2010;26:841-2.

704 20. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The
705 comprehensive antibiotic resistance database. *Antimicrob Agents Chemother*.
706 2013;57:3348-57.

707 21. Nayfach S, Pollard KS. Average genome size estimation improves comparative
708 metagenomics and sheds light on the functional ecology of the human microbiome.
709 *Genome Biol*. 2015;16:51.

710 22. Rodriguez-R LM, Konstantinidis KT. Nonpareil: a redundancy-based approach to assess
711 the level of coverage in metagenomic datasets. *Bioinformatics*. 2014;30:629-35.

712 23. Bushnell B. BBMAP. Available at: sourceforge.net/projects/bbmap/.

713 24. Li D, Liu C-M, Luo R, Sadakane K, Lam T-W. MEGAHIT: an ultra-fast single-node
714 solution for large and complex metagenomics assembly via succinct de Bruijn graph.
715 *Bioinformatics*. 2015;31:1674-6.

716 25. Mikheenko A, Saveliev V, Gurevich A. MetaQUAST: Evaluation of metagenome
717 assemblies. *Bioinformatics*. 2016;32.

718 26. Eren AM, Kiefl E, Shaiber A, Veseli I, Miller SE, Schechter MS, et al. Community-led,
719 integrated, reproducible multi-omics with anvi'o. *Nat Microbiol*. 2021;6:3-6.

720 27. Hyatt D, Chen G-L, Locascio PF, Land ML, Larimer FW, Hauser LJ: Prodigal:
721 prokaryotic gene recognition and translation initiation site identification. *BMC
722 Bioinform*. 2010;11:119.

723 28. Menzel P, Ng KL, Krogh A. Fast and sensitive taxonomic classification for
724 metagenomics with Kaiju. *Nat Commun*. 2016;7:11257.

725 29. Li Y, Xu Z, Han W, Cao H, Umarov R, Yan A, et al. HMD-ARG: hierarchical multi-task
726 deep learning for annotating antibiotic resistance genes. *Microbiome*. 2021;9.

727 30. Buchfink B, Xie C, Huson DH. Fast and sensitive protein alignment using DIAMOND.
728 *Nat Methods*. 2015;12:59-60.

729 31. Ma L, Xia Y, Li B, Yang Y, Li LG, Tiedje JM, et al. Metagenomic assembly reveals
730 hosts of antibiotic resistance genes and the shared resistome in pig, chicken, and human
731 feces. *Environ Sci Technol*. 2016;50:420-7.

732 32. Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D, et al. Package
733 'vegan': Community Ecology Package: Ordination, Diversity and Dissimilarities
734 2019;2(9). Available at: <https://cran.r-project.org/web/packages/vegan/vegan.pdf>

735 33. Ma S: MMUPHin: Meta-analysis methods with uniform pipeline for heterogeneity in
736 microbiome studies. Available at: <https://rdrr.io/bioc/MMUPHin/>

737 34. Lin H, Peddada SD. Analysis of compositions of microbiomes with bias correction. *Nat*
738 *Commun.* 2020;11.

739 35. Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut
740 microbiota dysbiosis: drivers, functional implications and recovery. *Curr Opin Microbiol.*
741 2018;44:34-40.

742 36. Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. Meta-analysis of gut
743 microbiome studies identifies disease-specific and shared responses. *Nat Commun.*
744 2017;8.

745 37. Clemente C, Jose, Ursell K, Luke, Parfrey W, Laura, Knight R. The impact of the gut
746 microbiota on human health: An integrative view. *Cell.* 2012;148:1258-70.

747 38. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al.
748 Enterotypes of the human gut microbiome. *Nature.* 2011;473:174-80.

749 39. Gibiino G, Lopetuso LR, Scaldaferri F, Rizzatti G, Binda C, Gasbarrini A. Exploring
750 Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals.
751 *Dig Liver Dis.* 2018;50:635-9.

752 40. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype
753 on the gut microbiome. *Nat Rev Microbiol.* 2011;9:279-90.

754 41. Feng J, Li B, Jiang X, Yang Y, Wells GF, Zhang T, et al. Antibiotic resistome in a large-
755 scale healthy human gut microbiota deciphered by metagenomic and network analyses.
756 *Environ Microbiol.* 2018;20:355-68.

757 42. Hu Y, Yang X, Qin J, Lu N, Cheng G, Wu N, et al. Metagenome-wide analysis of
758 antibiotic resistance genes in a large cohort of human gut microbiota. *Nat Commun.*
759 2013;4.

760 43. Scallan E, Crim SM, Runkle A, Henao OL, Mahon BE, Hoekstra RM, et al. Bacterial
761 enteric infections among older adults in the United States: Foodborne diseases active
762 surveillance network, 1996–2012. *Foodborne Pathog Dis.* 2015;12:492-9.

763 44. Scallan E, Mahon BE, Hoekstra RM, Griffin PM. Estimates of illnesses, hospitalizations
764 and deaths caused by major bacterial enteric pathogens in young children in the United
765 States. *Pediatr Infect Dis J.* 2013;32:217-21.

766 45. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-
767 mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of
768 Enterobacteriaceae. *Cell Host Microbe.* 2007;2:204.

769 46. Stecher B, Denzler R, Maier L, Bernet F, Sanders MJ, Pickard DJ, et al. Gut
770 inflammation can boost horizontal gene transfer between pathogenic and commensal
771 Enterobacteriaceae. *Proc Natl Acad Sci.* 2012;109:1269-74.

772 47. Skurnik D, Le Menac'H A, Zurakowski D, Mazel D, Courvalin P, Denamur E, et al.
773 Integreron-associated antibiotic resistance and phylogenetic grouping of *Escherichia coli*
774 isolates from healthy subjects free of recent antibiotic exposure. *Antimicrob Agents*
775 *Chemother.* 2005;49:3062-5.

776 48. Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and
777 inflammatory disease. *Curr Opin Immunol.* 2011;23:473-80.

778 49. Wales A, Davies R. Co-selection of resistance to antibiotics, biocides and heavy metals,
779 and its relevance to foodborne pathogens. *Antibiotics.* 2015;4:567-604.

780 50. Matchado MS, Lauber M, Reitmeier S, Kacprowski T, Baumbach J, Haller D, et al.
781 Network analysis methods for studying microbial communities: A mini review. *Comput*
782 *Struct Biotechnol J.* 2021;19:2687-98.

783 51. Shoemaker NB, Vlamakis H, Hayes K, Salyers AA. Evidence for extensive resistance
784 gene transfer among *Bacteroides* spp. and among *Bacteroides* and other genera in the
785 human colon. *Appl Environ Microbiol.* 2001;67:561-8.

786 52. Hedberg M, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic
787 Bacteria. Antimicrobial susceptibility of *Bacteroides fragilis* group isolates in Europe.
788 *Clin Microbiol Infect.* 2003;9:475-88.

789 53. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, et al.
790 Lessons learned from the anaerobe survey: Historical perspective and review of the most
791 recent data (2005-2007). *Clin Infect Dis.* 2010;50 Suppl 1:S26-33.

792 54. Teunis PFM, Evers EG, Hengeveld PD, Dierikx CM, Wielders CCCH, Van Duijkeren E.
793 Time to acquire and lose carriership of ESBL/pAmpC producing *E. coli* in humans in the
794 Netherlands. *PLoS One.* 2018;13:e0193834.

795 55. Doi Y, Adams-Haduch JM, Peleg AY, D'Agata EMC. The role of horizontal gene
796 transfer in the dissemination of extended-spectrum beta-lactamase-producing
797 *Escherichia coli* and *Klebsiella pneumoniae* isolates in an endemic setting. *Diag*
798 *Microbiol Infect Dis.* 2012;74:34-8.

799 56. Whittle G, Shoemaker NB, Salyers AA. The role of *Bacteroides* conjugative transposons
800 in the dissemination of antibiotic resistance genes. *Cell Mol Life Sci.* 2002;59:2044-54.

801 57. Shintani M, Sanchez ZK, Kimbara K: Genomics of microbial plasmids: Classification
802 and identification based on replication and transfer systems and host taxonomy. 6; 2015.

803 58. Carr VR, Shkorporov A, Hill C, Mullany P, Moyes DL. Probing the mobilome:
804 Discoveries in the dynamic microbiome. *Trends Microbiol.* 2021;29.

805